CY1112523T1 - Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο - Google Patents

Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο

Info

Publication number
CY1112523T1
CY1112523T1 CY20121100154T CY121100154T CY1112523T1 CY 1112523 T1 CY1112523 T1 CY 1112523T1 CY 20121100154 T CY20121100154 T CY 20121100154T CY 121100154 T CY121100154 T CY 121100154T CY 1112523 T1 CY1112523 T1 CY 1112523T1
Authority
CY
Cyprus
Prior art keywords
formulation
solvent
cannivoides
cannabinoids
liquid compositions
Prior art date
Application number
CY20121100154T
Other languages
English (en)
Inventor
Brian Anthony Whittle
Original Assignee
Gw Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218930A external-priority patent/GB2392093B/en
Priority claimed from US10/218,989 external-priority patent/US6946150B2/en
Application filed by Gw Pharma Limited filed Critical Gw Pharma Limited
Publication of CY1112523T1 publication Critical patent/CY1112523T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Η εφεύρεση σχετίζεται με φαρμακευτικές συνθέσεις και ειδικότερα με συνθέσεις που περιέχουν κανναβινοειδή για χορήγηση με σπρέι με την δράση αντλίας. Ειδικότερα η εφεύρεση σχετίζεται με φαρμακευτικές συνθέσεις, προς χρήση στην χορήγηση λιπόφιλων φαρμάκων που περιλαμβάνουν ένα ή περισσότερα κανναβινοειδή μέσω των επιφανειών βλεννογόνου, που περιλαμβάνουν: τουλάχιστον ένα λιπόφιλο φάρμακο που περιλαμβάνει ένα ή περισσότερα κανναβινοειδή, ένα διαλύτη και ένα συν-διαλύτη, όπου η συνολική ποσότητα του διαλύτη και του συν-διαλύτη που εμφανίζεται στην σύνθεση είναι μεγαλύτερη από 55 % του βάρους/ βάρος (wt/wt) της σύνθεσης, όπου η σύνθεση είναι απαλλαγμένη από ένα παράγοντα αυτόματης δημιουργίας γαλακτώματος και/ ή ενός φθοριωμένου προωθητικού υλικού και το κανναβινοειδές (κανναβινοειδή) εμφανίζεται (εμφανίζονται) στην σύνθεση με μία ποσότητα μεγαλύτερη από 10 mg/ml.
CY20121100154T 2002-08-14 2012-02-15 Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο CY1112523T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0218930A GB2392093B (en) 2002-08-14 2002-08-14 Pharmaceutical formulations
US10/218,989 US6946150B2 (en) 2002-08-14 2002-08-14 Pharmaceutical formulation
EP03787900A EP1542657B8 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal amdinistration

Publications (1)

Publication Number Publication Date
CY1112523T1 true CY1112523T1 (el) 2015-12-09

Family

ID=31889678

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100154T CY1112523T1 (el) 2002-08-14 2012-02-15 Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο

Country Status (16)

Country Link
EP (2) EP1542657B8 (el)
JP (1) JP4515908B2 (el)
KR (1) KR101008609B1 (el)
AT (1) ATE533472T1 (el)
AU (2) AU2003253005B2 (el)
CA (1) CA2454644C (el)
CY (1) CY1112523T1 (el)
DK (2) DK2314284T3 (el)
ES (2) ES2377819T3 (el)
FR (1) FR14C0025I2 (el)
LU (1) LU92233I2 (el)
MX (1) MXPA05001567A (el)
PL (1) PL215220B1 (el)
PT (2) PT2314284T (el)
SI (1) SI1542657T1 (el)
WO (1) WO2004016246A1 (el)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782991B2 (en) 2000-03-09 2005-09-15 GW Research Limited Pharmaceutical compositions
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US9035130B2 (en) 2007-05-31 2015-05-19 Gw Pharma Limited Reference plant, a method for its production, extracts obtained therefrom and their use
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2491118B (en) 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) * 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
BR112017014375A2 (pt) * 2014-07-18 2019-12-31 Medipath Inc composições e métodos para administração fisiológica usando canabidiol.
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
EP3209312A1 (en) 2014-10-21 2017-08-30 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
PL3236967T3 (pl) 2014-12-22 2020-04-30 Suda Pharmaceuticals Ltd Zapobieganie i leczenie przerzutów u pacjentów z nadpłytkowością typu nowotworowego
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10188628B1 (en) 2016-10-27 2019-01-29 Alvin Kershman Release composition for derivatives of Cannabaceae
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
EP3600361A4 (en) 2017-03-24 2021-01-06 Trait Biosciences, Inc. HIGH LEVEL IN VIVO BIOSYNTHESIS AND ISOLATION OF WATER-SOLUBLE CANNABINOIDS IN PLANT SYSTEMS
CN111465700A (zh) 2017-07-11 2020-07-28 特征生物科学公司 在酵母和植物细胞悬浮培养物中产生水溶性大麻素化合物和材料组合物
US11946059B2 (en) 2017-07-11 2024-04-02 Trait Biosciences, Inc. In vivo generation of water-soluble cannabinoids in plant cell suspension cultures
US11905543B2 (en) 2017-07-11 2024-02-20 Trait Biosceinces, Inc. In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures
AU2018101357B4 (en) * 2017-09-15 2022-03-17 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
US20200289459A1 (en) * 2017-11-30 2020-09-17 Canopy Growth Corporation Liquid dosage forms, methods of making and use
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
CN112672740A (zh) * 2018-06-15 2021-04-16 康宝动物治疗有限公司 大麻素组合物以及使用大麻素组合物的治疗方法
US11504416B2 (en) 2018-09-04 2022-11-22 Paw Power, Inc. Formulation with cannabinoids
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
KR102445087B1 (ko) * 2019-05-03 2022-09-20 자이우스 라이프 사이언시스 아이엔씨. 통증 관리용 제형
US20220264947A1 (en) * 2019-07-22 2022-08-25 Angus RITTENBURG Cartridge for dispensing products and methods for their manufacture
WO2021055937A1 (en) * 2019-09-20 2021-03-25 Good Design, Inc. Cartridge for dispensing products and methods for their manufacture
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
IL303176A (en) 2020-11-24 2023-07-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Cannabinoid derivatives and their use to treat inflammation and/or pain and/or obesity
KR102489407B1 (ko) * 2021-01-18 2023-01-17 주식회사 네이처센스 대마 추출물을 유효성분으로 포함하는 통증 완화 및 스트레스 관련 질환 예방 및 개선용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560625A (en) 1967-02-20 1971-02-02 Colgate Palmolive Co Method of,and formulations for,introducing alkoxybenzamides into the systemic circulatory system
DE3522550A1 (de) 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung
US5165093A (en) * 1992-03-23 1992-11-17 The Titan Corporation Interstitial X-ray needle
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
EP1109533A1 (en) * 1999-07-08 2001-06-27 Orlando Hung Pulmonary delivery of liposome-encapsulated cannabinoids
DE19936911A1 (de) 1999-08-05 2001-02-08 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
NZ517517A (en) * 1999-08-20 2004-03-26 Unimed Pharmaceuticals Inc Composition for inhalation comprising delta-9- tetrahydrocannabinol in a semiaqueous solvent
GB9927555D0 (en) * 1999-11-23 2000-01-19 Bede Scient Instr Ltd X-ray fluorescence apparatus
AU782991B2 (en) 2000-03-09 2005-09-15 GW Research Limited Pharmaceutical compositions
JP2004532185A (ja) * 2001-01-26 2004-10-21 ユニバーシティ オブ コネチカット 新規なカンナビミメティックリガンド
DE10296335T5 (de) 2001-02-14 2004-04-15 G W Pharma Ltd., Salisbury Pharmazeutische Formulierungen
EP1321159A1 (en) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices

Also Published As

Publication number Publication date
PT2314284T (pt) 2017-05-25
CA2454644C (en) 2014-09-16
ATE533472T1 (de) 2011-12-15
EP2314284A3 (en) 2012-05-09
EP1542657A1 (en) 2005-06-22
AU2003253005A1 (en) 2004-03-03
FR14C0025I2 (fr) 2014-11-14
ES2377819T3 (es) 2012-04-02
EP2314284A2 (en) 2011-04-27
KR101008609B1 (ko) 2011-01-17
LU92233I2 (fr) 2013-08-26
AU2009202434B2 (en) 2012-08-30
PL375224A1 (en) 2005-11-28
FR14C0025I1 (el) 2014-08-08
DK1542657T3 (da) 2012-03-05
CA2454644A1 (en) 2004-02-14
EP1542657B8 (en) 2012-03-14
JP2006504671A (ja) 2006-02-09
AU2003253005B2 (en) 2009-03-19
JP4515908B2 (ja) 2010-08-04
PT1542657E (pt) 2012-02-29
PL215220B1 (pl) 2013-11-29
SI1542657T1 (sl) 2012-04-30
EP1542657B1 (en) 2011-11-16
ES2625605T3 (es) 2017-07-20
AU2009202434A1 (en) 2009-07-09
MXPA05001567A (es) 2005-04-25
DK2314284T3 (en) 2017-05-22
WO2004016246A1 (en) 2004-02-26
KR20050042157A (ko) 2005-05-04
EP2314284B1 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
CY1112523T1 (el) Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο
BR9810729B1 (pt) composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante.
DE60126599D1 (de) Cannabis enthaltende pharmazeutische zusammensetzungen
WO2006003481A3 (en) Oleaginous pharmaceutical and cosmetic foam
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
EA199900991A1 (ru) Медицинские аэрозольные препараты
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
JP2003183157A (ja) 眼科用組成物
AR033688A1 (es) Composicion parenteral reconstituible
ATE549015T1 (de) Pharmazeutische wirkstoffhaltige formulierung mit überzug
BR0317340A (pt) Formulações de hfc em solução contendo tiotrópio
CL2004001325A1 (es) Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas.
AR039388A1 (es) Formulaciones liquidas de baja dosis de entecavir y uso
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
MY126358A (en) Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
JP2005187404A (ja) 粘膜外用噴霧組成物、点鼻剤及び口腔・咽喉疾患用剤
JP2001039922A (ja) ソルビン酸類の分解抑制方法及び液剤組成物
TH63200A (th) สูตรผสมเอนทีคาเวอร์ชนิดของเหลวที่มีขนาดการใช้ยาต่ำ และการใช้
KR950016757A (ko) 약물중독 치료제 조성물